23 research outputs found
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial
BACKGROUND: In addition to its known properties as a competitive,
nonselective beta and alpha-1 receptor blocker, carvedilol directly
inhibits vascular myocyte migration and proliferation and exerts
antioxidant effects that are considerably greater than those of vitamin E
or probucol. This provides the basis for an evaluation of carvedilol for
the prevention of coronary restenosis. METHODS AND RESULTS: In a
prospective, double-blind, randomized, placebo-controlled trial, 25 mg of
carvedilol was given twice daily, starting 24 h
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease
The recommendations listed in this document are, whenever possible, evidence based. An extensive evidence review was conducted as the document was compiled through December 2008. Repeated literature searches were performed by the guideline development staff and writing committee members as new issues were considered. New clinical trials published in peer-reviewed journals and articles through December 2011 were also reviewed and incorporated when relevant. Furthermore, because of the extended development time period for this guideline, peer review comments indicated that the sections focused on imaging technologies required additional updating, which occurred during 2011. Therefore, the evidence review for the imaging sections includes published literature through December 2011